200,000+ products from a single source!
sales@angenechem.com
Home > Quinoline > 248281-84-7
248281-84-7 | 3-Quinolinecarboxamide, 5-chloro-N-ethyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxo-N-phenyl-
CAS No: 248281-84-7 Catalog No: AG002PL7 MDL No:MFCD08689859
Product Description
Catalog Number:
AG002PL7
Chemical Name:
3-Quinolinecarboxamide, 5-chloro-N-ethyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxo-N-phenyl-
CAS Number:
248281-84-7
Molecular Formula:
C19H17ClN2O3
Molecular Weight:
356.8029
MDL Number:
MFCD08689859
IUPAC Name:
5-chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenylquinoline-3-carboxamide
InChI:
InChI=1S/C19H17ClN2O3/c1-3-22(12-8-5-4-6-9-12)19(25)16-17(23)15-13(20)10-7-11-14(15)21(2)18(16)24/h4-11,23H,3H2,1-2H3
InChI Key:
GKWPCEFFIHSJOE-UHFFFAOYSA-N
SMILES:
CCN(C(=O)c1c(O)c2c(Cl)cccc2n(c1=O)C)c1ccccc1
UNII:
908SY76S4G
Properties
Complexity:
571
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
356.093g/mol
Formal Charge:
0
Heavy Atom Count:
25
Hydrogen Bond Acceptor Count:
3
Hydrogen Bond Donor Count:
1
Isotope Atom Count:
0
Molecular Weight:
356.806g/mol
Monoisotopic Mass:
356.093g/mol
Rotatable Bond Count:
3
Topological Polar Surface Area:
60.8A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
3.7
Literature
| Title | Journal |
|---|---|
| In vitro toxicity and in silico docking analysis of two novel selective AH-receptor modulators. | Toxicology in vitro : an international journal published in association with BIBRA 20181001 |
| Toxicological characterisation of two novel selective aryl hydrocarbon receptor modulators in Sprague-Dawley rats. | Toxicology and applied pharmacology 20170701 |
| Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis. | Journal of neuroimmunology 20121015 |
| Laquinimod modulates B cells and their regulatory effects on T cells in multiple sclerosis. | Journal of neuroimmunology 20121015 |
| Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination. | Acta neuropathologica 20120901 |
| Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod. | The American journal of pathology 20120801 |
| Oral laquinimod for multiple sclerosis. | The New England journal of medicine 20120628 |
| Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II). | Revista de neurologia 20120616 |
| Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. | Bone marrow transplantation 20120601 |
| Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis. | Expert review of clinical pharmacology 20120501 |
| Drugs: An injection of hope. | Nature 20120412 |
| Placebo-controlled trial of oral laquinimod for multiple sclerosis. | The New England journal of medicine 20120315 |
| New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis. | Current opinion in neurology 20120201 |
| Immune mechanisms of new therapeutic strategies in MS: teriflunomide. | Clinical immunology (Orlando, Fla.) 20120101 |
| Laquinimod in multiple sclerosis. | Clinical immunology (Orlando, Fla.) 20120101 |
| Current concepts of hyperinflammation in chronic granulomatous disease. | Clinical & developmental immunology 20120101 |
| Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. | The American journal of pathology 20120101 |
| Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis. | Clinical & developmental immunology 20120101 |
| Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. | PloS one 20120101 |
| Immune therapy of multiple sclerosis--future strategies. | Current pharmaceutical design 20120101 |
| Current therapeutic options in pediatric multiple sclerosis. | Current treatment options in neurology 20111201 |
| Emerging oral drugs for relapsing-remitting multiple sclerosis. | Expert opinion on emerging drugs 20111201 |
| Oral treatment for multiple sclerosis. | The Lancet. Neurology 20111101 |
| Multiple sclerosis: pathogenesis and treatment. | Current neuropharmacology 20110901 |
| Insight into the mechanism of laquinimod action. | Journal of the neurological sciences 20110715 |
| Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon β-1α: A randomized controlled trial. | Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences 20110401 |
| Oral laquinimod treatment in multiple sclerosis. | Neurologia (Barcelona, Spain) 20110301 |
| Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis. | Expert opinion on drug metabolism & toxicology 20110301 |
| [Current treatment of multiple sclerosis]. | Lege artis medicinae : uj magyar orvosi hirmondo 20110201 |
| Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved. | CNS drugs 20110101 |
| Therapeutic approach to multiple sclerosis by novel oral drug. | Recent patents on inflammation & allergy drug discovery 20110101 |
| Multiple sclerosis therapeutic pipeline: opportunities and challenges. | The Mount Sinai journal of medicine, New York 20110101 |
| Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents. | Patient preference and adherence 20110101 |
| Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis. | Core evidence 20110101 |
| Development of oral immunomodulatory agents in the management of multiple sclerosis. | Drug design, development and therapy 20110101 |
| The involvement of neuroinflammation and kynurenine pathway in Parkinson's disease. | Parkinson's disease 20110101 |
| The impact of utilizing different optical coherence tomography devices for clinical purposes and in multiple sclerosis trials. | PloS one 20110101 |
| Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis. | ASN neuro 20110101 |
| Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study. | BMC neurology 20110101 |
| Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. | Multiple sclerosis (Houndmills, Basingstoke, England) 20101101 |
| Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. | Journal of neuroimmunology 20101008 |
| Current and future role of interferon beta in the therapy of multiple sclerosis. | Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 20101001 |
| Emerging therapies in relapsing-remitting multiple sclerosis. | Reviews on recent clinical trials 20100901 |
| Treatment options for multiple sclerosis: current and emerging therapies. | Pharmacotherapy 20100901 |
| Emerging oral agents for multiple sclerosis. | The American journal of managed care 20100901 |
| Will the newer oral MS agents be welcomed by managed care organizations? | The American journal of managed care 20100901 |
| New drug therapies for multiple sclerosis. | Current opinion in neurology 20100601 |
| Laquinimod, a new oral autoimmune modulator for the treatment of relapsing-remitting multiple sclerosis. | Current opinion in investigational drugs (London, England : 2000) 20100501 |
| Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study. | Journal of neuroimmunology 20100415 |
| Multiple sclerosis: a supplement on the disease state, current therapies, and investigational treatments. | Journal of pharmacy practice 20100401 |
| Emerging multiple sclerosis oral therapies. | Neurology 20100105 |
| A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. | PloS one 20100101 |
| Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. | Patient preference and adherence 20100101 |
| Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis. | Therapeutics and clinical risk management 20100101 |
| Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine. | Drug design, development and therapy 20100101 |
| Multiple sclerosis therapies: molecular mechanisms and future. | Results and problems in cell differentiation 20100101 |
| Disease-modifying therapies in relapsing-remitting multiple sclerosis. | Neuropsychiatric disease and treatment 20100101 |
| Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tablets. | Therapeutics and clinical risk management 20100101 |
| New approaches in the management of multiple sclerosis. | Drug design, development and therapy 20100101 |
| Emerging therapies for treatment of multiple sclerosis. | Journal of inflammation research 20100101 |
| The future of multiple sclerosis therapy. | Pharmacological research 20091001 |
| New oral drugs for multiple sclerosis. | Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20091001 |
| Oral laquinimod therapy in relapsing multiple sclerosis. | Expert opinion on investigational drugs 20090701 |
| Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. | PLoS biology 20090401 |
| Recent advances in the treatment of amyotrophic lateral sclerosis. Emphasis on kynurenine pathway inhibitors. | Central nervous system agents in medicinal chemistry 20090301 |
| Review of teriflunomide and its potential in the treatment of multiple sclerosis. | Neuropsychiatric disease and treatment 20090101 |
| Recent developments in multiple sclerosis therapeutics. | BMC medicine 20090101 |
| Promising treatments of tomorrow for multiple sclerosis. | Annals of Indian Academy of Neurology 20090101 |
| New oral disease-modifying therapies for multiple sclerosis. | F1000 medicine reports 20090101 |
| Kynurenine pathway metabolites in humans: disease and healthy States. | International journal of tryptophan research : IJTR 20090101 |
| Identification and development of new therapeutics for multiple sclerosis. | Trends in pharmacological sciences 20081101 |
| Emerging oral drugs for multiple sclerosis. | Expert opinion on emerging drugs 20080901 |
| Oral laquinimod for treatment of relapsing-remitting multiple sclerosis. | The Lancet. Neurology 20080801 |
| Laquinimod, a new oral drug for multiple sclerosis. | Lancet (London, England) 20080621 |
| Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. | Lancet (London, England) 20080621 |
| Evaluation of the effects of a new drug candidate (GEMSP) in a chronic EAE model. | International journal of biological sciences 20080101 |
| Disease-modifying agents for multiple sclerosis: recent advances and future prospects. | Drugs 20080101 |
| Novel oral agents for multiple sclerosis. | Current neurology and neuroscience reports 20070501 |
| Oral disease-modifying treatments for multiple sclerosis: the story so far. | CNS drugs 20070101 |
| Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice. | Journal of neuroimmunology 20060401 |
| Synthesis and reactivity of laquinimod, a quinoline-3-carboxamide: intramolecular transfer of the enol proton to a nitrogen atom as a plausible mechanism for ketene formation. | The Journal of organic chemistry 20060217 |
| Determination of the immunomodulator laquinimod in human plasma by liquid chromatography/tandem mass spectrometry; development, validation and application of two methods in clinical pharmacokinetic profiling. | Rapid communications in mass spectrometry : RCM 20060101 |
| Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator. | Drug metabolism and disposition: the biological fate of chemicals 20050601 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20050601 |
| Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. | Neurology 20050322 |
| [Future possibilities of the multiple sclerosis treatment]. | Casopis lekaru ceskych 20050101 |
| Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. | Journal of neuroimmunology 20041101 |
| Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. | Journal of medicinal chemistry 20040408 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20040101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20040101 |
| Determination of laquinimod in plasma by coupled-column liquid chromatography with ultraviolet absorbance detection. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030305 |
| The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. | Journal of neuroimmunology 20020901 |
| Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. | Neuropharmacology 20020401 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.